Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 8 records in total 8
    records per page




    Impact of Corticosteroids and Immunosuppressive Therapies on Symptomatic SARS-CoV-2 Infection MESHD in a Large Cohort of Patients with Chronic Inflammatory Arthritis MESHD Arthritis HP

    Authors: Ennio Giulio Favalli; Serena Bugatti; Catherine Klersy; Martina Biggioggero; Silvia Rossi; Orazio De Lucia; Francesca Bobbio-Pallavicini; Antonella Murgo; Silvia Balduzzi; Roberto Caporali; Carlomaurizio Montecucco

    doi:10.21203/rs.3.rs-51667/v1 Date: 2020-07-31 Source: ResearchSquare

    Background: Prevalence SERO and outcomes of Coronavirus Disease MESHD (COVID)-19 in relation to immunomodulatory medications are still unknown. The aim of the study is to investigate the impact of glucocorticoids and immunosuppressive agents on COVID-19 in a large cohort of patients with chronic immune-mediated inflammatory arthritis MESHD arthritis HP.Methods: The study was conducted in the arthritis MESHD arthritis HP outpatient clinic at two large Academic Hospitals in the COVID-19 most endemic area of Northern Italy (Lombardy). We circulated a cross-sectional survey exploring the prevalence SERO of Severe Acute Respiratory Syndrome MESHD-Coronavirus-2 nasopharyngeal swab positivity and the occurrence of acute respiratory illness ( fever MESHD fever HP and/or cough MESHD cough HP and/or dyspnea MESHD dyspnea HP), administered face-to-face or by phone to consecutive patients from 25th February to 20th April 2020. COVID-19 cases were defined as confirmed or highly suspicious according to the World Health Organization criteria. The impact of medications on COVID-19 incidence was evaluated. Results: The study population included 2050 adults TRANS with chronic inflammatory arthritis MESHD arthritis HP receiving glucocorticoids, conventional-synthetic (cs), or targeted-synthetic/biological (ts/b) disease MESHD-modifying drugs (DMARDs). Laboratory-confirmed COVID-19 and highly suspicious infection MESHD were recorded in 1.1% and 1.4% of the population, respectively. Treatment with glucocorticoids was independently associated with increased risk of COVID-19 (adjusted OR [95% CI] ranging from 1.23 [1.04-1.44] to 3.20 [1.97-5.18] depending on the definition used). Conversely, patients treated with ts/bDMARDs were at reduced risk (adjusted OR ranging from 0.46 [0.18-1.21] to 0.47 [0.46-0.48]). No independent effects of csDMARDs were observed.Conclusions: During the COVID-19 outbreak, treatment with immunomodulatory medications appears safe. Conversely, glucocorticoids, even at low-dose, may confer increased risk of infection TRANS risk of infection TRANS infection MESHD.Trial registration:  retrospectively registered

    Transcriptional response modules characterise IL-1 and IL-6 activity in COVID-19

    Authors: Lucy C K Bell; Mahdad Noursadeghi; Gabriele Pollara

    doi:10.1101/2020.07.22.202275 Date: 2020-07-23 Source: bioRxiv

    Dysregulated IL-1 and IL-6 responses have been implicated in the pathogenesis of severe Coronavirus Disease MESHD 2019 (COVID-19). Innovative approaches for evaluating the biological activity of these cytokines in vivo are urgently needed to complement clinical trials of therapeutic targeting of IL-1 and IL-6 in COVID-19. We show that the expression of IL-1 or IL-6 inducible transcriptional signatures (modules) reflects the bioactivity of these cytokines in juvenile idiopathic arthritis MESHD arthritis HP (JIA) and rheumatoid arthritis MESHD rheumatoid arthritis HP, and discerns the effect of therapeutic cytokine blockade in JIA. In COVID-19, elevated expression of IL-1 and IL-6 response modules, but not these cytokines per se, is a feature of disease MESHD both in blood SERO and in affected organs. We propose that IL-1 and IL-6 transcriptional response modules can provide a dynamic readout of the activity of these cytokine pathways in vivo, with potential applications for identifying COVID-19 patients who may benefit from IL-1 or IL-6 blocking therapy, and to aid quantification of the biological effects of these treatments.

    The impact of the COVID-19 Pandemic on Patients with Chronic Rheumatic Diseases MESHD: A Study in 15 Arab Countries

    Authors: Nelly Ziade; Lina el Kibbi; Ihsane Hmamouchi; Nizar Abdulateef; Hussein Halabi; Wafa Hamdi; Fatemah Abutiban; Manal el Rakawi; Mervat Eissa; Basel Masri

    doi:10.21203/rs.3.rs-40892/v1 Date: 2020-07-09 Source: ResearchSquare

    Aim. To evaluate the impact of the Coronavirus Disease MESHD 2019 pandemic (COVID-19) on the access to rheumatology care for patients with chronic rheumatic diseases MESHD (CRD) in the Arab countries.Method. A web-based cross-sectional survey was designed by the Arab Adult TRANS Arthritis MESHD Arthritis HP Awareness group (AAAA) consisting of 16 rheumatologists representing countries from the Arab League of Associations for Rheumatology (ArLAR), and was validated by the ArLAR scientific committee. The survey was disseminated through social media and patients' associations' channels between May 8 and May 22, 2020. The steering committee developed recommendations to improve the care of patients with CRD during the COVID-19 pandemic.Results. A total of 2163 patients were included in the analysis; 72% were females TRANS; mean age TRANS was 40 years (SD 11.9). The Levant, the Gulf, and North Africa contributed almost equally to the sample. The pandemic had a significant negative impact on rheumatology visits in 82% of cases, on access to hydroxychloroquine (47%), and on chronic medication persistency (28%). The negative impact on rheumatology visits was associated with female TRANS gender TRANS, country, medication non-persistency, isolation due to COVID-19, and impact on mental health. Sixty-one patients (2.8%) stated that they had COVID-19, 5% said that a close contact TRANS was infected, and 47% were in isolation because of COVID-19.Conclusion. The current study highlights the deleterious consequences of the COVID-19 pandemic on the continuity of rheumatology care. Therefore, an action plan, including establishing a telemedicine platform, securing drug availability, and promoting medication persistence through the appropriate communication channels, is strongly recommended.

    Does Biological Therapy Protect against Severe COVID-19?

    Authors: Ramon Mazzucchelli; Raquel Almodovar-Gonzalez; Natalia Crespi-Villarias; Elena Garcia-Zamora; Elia Perez-Fernandez; Javier Quiros-Donate; Monserrat Perez-Encinas; Patricia Sanmartin-Fenollera; Maria Velasco-Arribas; Pilar Lopez-Serrano; Jose lazaro Perez-Calle; Conrado Fernandez-Rodriguez; Jose Luis Lopez-Estebaranz; Pedro Zarco-Montejo

    doi:10.1101/2020.06.21.20136788 Date: 2020-06-24 Source: medRxiv

    Objective. To estimate COVID-19 infection MESHD incidence rate with severe affectation (requiring hospitalization) in patients with biological treatment due to rheumatoid arthritis MESHD rheumatoid arthritis HP (RA), psoriatic arthritis MESHD arthritis HP (PsA), spondyloarthritis (SpA), psoriasis MESHD (Ps), and inflammatory bowel disease MESHD (IBD) and compare it with incidence rate in the general population. Methods: Retrospective observational study based on information provided by two administrative databases. One of these two databases contains information on all patients seen in our hospital and diagnosed with COVID-19 infection MESHD between March 4th 2020 and April 26th 2020. The other database contains data from patients seen at Rheumatology, Dermatology and Digestive Departments in our hospital who are currently receiving biological therapy. We calculated the crude and age TRANS and sex adjusted incidence in both groups. To compare both groups we calculated the Incidence Rate Ratio. Results: There was a total of 2,182 patients with COVID-19 requiring hospitalization. Four patients out of a total of 797 patients receiving biological therapy had contracted COVID-19 and required hospital care. Crude incidence rate of COVID-19 requiring hospital care among the general population was 1.41%, and it was 0.50% among the group receiving biological therapy. Rates adjusted by age TRANS and sex in the biological group was 0.45% (CI95% 0.11-4.13). The IRR of the group receiving biological therapy compared to the general population was 0.39 (CI95% 0.14-1, p=0.049). Conclusion: Findings suggest that prior use of biological therapy does not associate with severe manifestations of COVID-19, and it is likely to have a protective effect against them when compared to the general population.

    Clinical Outcomes of Patients with COVID-19 and Chronic Inflammatory and Autoimmune Rheumatic Diseases MESHD: A Multicentric Matched-Cohort Study

    Authors: José L Pablos; María Galindo; Loreto Carmona; Miriam Retuerto; Ana Lledó; Ricardo Blanco; Miguel A. González-Gay; David Martínez-López; Isabel Castrejón; José M. Alvaro-Gracia; David Fernández-Fernández; Antonio Mera-Varela; Sara Manrique-Arija; Natalia Mena-Vázquez; Antonio Fernández-Nebro; - RIER investigators group

    doi:10.1101/2020.06.18.20133645 Date: 2020-06-20 Source: medRxiv

    ABSTRACT Background The impact of inflammatory rheumatic diseases MESHD on COVID-19 severity is poorly known. Here we compare the outcomes of a cohort of rheumatic patients with a matched control cohort to identify potential risk factors for severe illness. Methods In this comparative cohort study, we identified hospital PCR+ COVID-19 rheumatic patients with chronic inflammatory arthritis MESHD arthritis HP (IA) or autoimmune/immunomediated diseases MESHD (AI/IMID). Non-rheumatic controls were randomly sampled 1:1, and matched by age TRANS, sex, and PCR date. The main outcome was severe COVID-19, defined as death MESHD, invasive ventilation, ICU admission, or serious complications. We assessed the association between the outcome and potential prognostic variables, adjusted by COVID treatment, using logistic regression. Results The cohorts were composed of 456 rheumatic and non-rheumatic patients, in equal numbers. Mean age TRANS was 63 [IQR 53-78] and male TRANS sex 41% in both cohorts. Rheumatic diseases MESHD were IA (60%) and AI/IMID (40%). Most patients (74%) had been hospitalised, and the risk of severe COVID was 31.6% in the rheumatic and 28.1% in the non-rheumatic cohort. Ageing, male TRANS sex and previous comorbidity ( obesity MESHD obesity HP, diabetes, hypertension MESHD hypertension HP, cardiovascular, or lung disease MESHD) increased the risk in the rheumatic cohort by bivariate analysis. In logistic regression analysis, independent factors associated with severe COVID were increased age TRANS (OR 5.31; CI 3.14-8.95), male TRANS sex (2.13; CI 1.35-3.36) and having an AI/IMID (OR 1.98; CI 1.15-3.41). Conclusion In patients with chronic inflammatory rheumatic diseases MESHD aging, sex and having an AI/IMID but not IA nor previous immunosuppressive therapies were associated with severe COVID-19.

    The impact of COVID-19 pandemic on pediatric rheumatology patients under immunosuppressive therapy: A single-center experience

    Authors: Oya Koker; Fatma Gul Demirkan; Gulsah Kayaalp; Figen Cakmak; Ayse Tanatar; Serife Gul Karadag; Emine Sonmez; Rukiye Omeroglu; Nuray Aktay Ayaz

    doi:10.21203/rs.3.rs-36583/v1 Date: 2020-06-19 Source: ResearchSquare

    Objective: The aim of the research was to further broaden current knowledge of whether severe acute respiratory syndrome MESHD coronavirus 2 (SARS-CoV-2) disease MESHD 2019 (COVID-19) entails a risk for children TRANS with rheumatic diseases MESHD regarding immunosuppressive treatment.Methods: Telephone-survey was administered by conducting interviews with the parents TRANS. A message containing a link to the actual questionnaire was sent to their phones simultaneously. The medical records of the patients were reviewed for gathering information about demographic data, clinical follow-up, and treatments.Results: Patients who were followed up with immunosuppressive treatment (n=439) were attempted to be contacted between 1 May 2020 and 15 May 2020. The diagnostic distribution of patients who were accessible and eligible for the study was as follows; juvenile idiopathic arthritis MESHD arthritis HP (JIA) (n=243, 58.7%), autoinflammatory diseases MESHD (n=109, 26.3%), autoimmune connective tissue diseases MESHD (n=51, 12.3%) and vasculitis MESHD vasculitis HP (n=11, 2.7%). In the entire cohort, the mean age TRANS was 12 ± 4.7 years, and 54.1% (n=224) of the patients were female TRANS. One patient with seronegative polyarticular JIA, previously prescribed methotrexate and receiving leflunomide during pandemic has been identified to be diagnosed with COVID-19. None of the patients, including the patient diagnosed with COVID-19, had any severe symptoms. More than half of the patients with household contacts TRANS required hospitalization as they were asymptomatic TRANS.Conclusion: Although circumstances such as compliance in social distancing policy, transmission TRANS patterns, attitude following contact may influence the results, immunosuppressive treatment does not seem to pose additional risk in terms of COVID-19.

    Ethnically diverse mutations in PIEZO1 associate with SARS-CoV-2 positivity

    Authors: Chew W Cheng; Vijayalakshmi Deivasikamani; Melanie J Ludlow; Dario De Vecchis; Antreas C Kalli; David J Beech; Piruthivi Sukumar

    doi:10.1101/2020.06.01.20119651 Date: 2020-06-03 Source: medRxiv

    COVID-19, caused by the SARS-CoV-2 virus, carries significant risk of mortality and has spread globally with devastating societal consequences. Endothelial infection MESHD has been identified as a feature of the disease MESHD and so there is motivation to determine the relevance of endothelial membrane mechanisms affecting viral entry and response. Here, through a study of patient data in UK Biobank released on 16 April 2020, we suggest relevance of PIEZO1, a non-selective cation channel protein that both mediates endothelial responses to mechanical force and unusually indents the cell membrane. PIEZO1 notably has roles that may also be relevant in red blood SERO cell function, pulmonary inflammation MESHD, bacterial infection MESHD and fibrotic auto- inflammation MESHD. We provide evidence that single nucleotide polymorphisms (SNPs) in the gene encoding PIEZO1 are more common in individuals who test positive for SARS-CoV-2 regardless of pre-existing hypertension MESHD hypertension HP, myocardial infarction MESHD myocardial infarction HP, stroke MESHD stroke HP, diabetes mellitus MESHD diabetes mellitus HP or arthritis MESHD arthritis HP. Some of these SNPs are more common in African and Caribbean populations, which are groups that were recently shown to have greater susceptibility to infection MESHD. One of the SNPs is a missense mutation that results in an amino acid change in an evolutionarily conserved and previously unexplored N-terminal region PIEZO1. The data support the notion of genetic factors influencing SARS-CoV-2 infection MESHD and suggest a specific role for PIEZO1.

    Prevalence SERO of Hospital PCR Confirmed Covid-19 Cases in Patients with Chronic Inflammatory and Autoimmune Rheumatic Diseases MESHD

    Authors: José L. Pablos; Lydia Abasolo-Alcázar; José M. Álvaro-Gracia; Francisco J. Blanco; Ricardo Blanco; Isabel Castrejón; David Fernández-Fernández; Benjamín Fernández-Gutierrez; María Galindo; Miguel A. González-Gay; Sara Manrique-Arija; Natalia Mena-Vázquez; Antonio Mera-Varela; Miriam Retuerto; Álvaro Seijas-Lopez; - RIER investigators group

    doi:10.1101/2020.05.11.20097808 Date: 2020-05-14 Source: medRxiv

    ABSTRACT Background. The susceptibility of patients with rheumatic diseases MESHD, and the risks or benefits of immunosuppressive therapies for COVID-19 are unknown. Methods. We performed a retrospective study with patients under follow-up in rheumatology departments from seven hospitals in Spain. We matched updated databases of rheumatology patients with SARS-CoV-2 positive PCR tests performed in the hospital to the same reference populations. Incidences of PCR+ confirmed COVID-19 were compared among groups. Results. Patients with chronic inflammatory diseases MESHD had 1.32-fold higher prevalence SERO of hospital PCR+ COVID-19 than the reference population (0.76% vs 0.58%). Systemic autoimmune or immune mediated diseases MESHD (AI/IMID) patients showed a significant increase, whereas inflammatory arthritis MESHD arthritis HP (IA) or systemic lupus erythematosus MESHD systemic lupus erythematosus HP (SLE) patients did not. COVID-19 cases in some but not all diagnostic groups had older ages TRANS than cases in the reference population. IA patients on targeted-synthetic or biological disease MESHD-modifying antirheumatic drugs (ts/bDMARD), but not those on conventional-synthetic (csDMARD), had a greater prevalence SERO despite a similar age TRANS distribution. Conclusion. Patients with AI/IMID show a variable risk of hospital diagnosed COVID-19. Interplay of aging, therapies, and disease MESHD specific factors seem to contribute. These data provide a basis to improve preventive recommendations to rheumatic patients and to analyze the specific factors involved in COVID-19 susceptibility.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.